PubMed HealthSearch

Biomedical subjects

L Chauvelot-Moachon

Publications and source records attributed to L Chauvelot-Moachon.

18 recordsLinked to original sources

[Activity of adenosine in relation to tumor necrosis factor (TNF). Therapeutic outlook].

At physiological and pharmacological doses, adenosine protects tissues against a varieties of injuries: ischemia-reperfusion, convulsions, inflammation.... We tested the hypothesis that the antiinflammatory properties of adenosine occur via a down-regulation of TNF. Agonists of adenosine receptors (ARA) and agents potentiating endogenous adenosine (APA) were evaluated for their effects on TNF production by endotoxin-stimulated human monocytes. Additionally, one of the most potent agonists, R-phenylisopropyladenosine (R-PIA), was tested on two experimental models of acute phase response, endotoxin shock and carrageenan-induced plantar oedema. Several ARA and APA inhibited monocyte TNF production in a concentration-dependent manner. R-PIA and other ARA were active at micromolar concentrations. The property is pharmacologically relevant since rats receiving a lethal dose of endotoxins were protected by R-PIA and endotoxin-induced serum TNF levels were abolished by a pretreatment with R-PIA. Inhibitory effects on serum TNF production were obtained with similar doses of dexamethasone sodium phosphate and one hundred-fold higher doses of pentoxifylline. R-PIA was also found active on carrageenan-induced oedema. The anti-oedematous properties of R-PIA were associated with a marked reduction of locally-produced TNF and were also observed after the administration of dexamethasone, pentoxifylline and a neutralizing anti-TNF antibody. Our results indicate that adenosine is a potent inhibitor of TNF production induced by different stimuli. This property could lead to therapeutic applications in inflammatory diseases and other in which TNF is known to play a pathogenic or aggravating role. Comparison between ARA and APA in terms of tolerance and efficacy merits further attention.

Adenosine

Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses.

Dexamethasone (sodium phosphate), pentoxifylline, fusidic acid (sodium salt), pentamidine (isethionate) and R-phenylisopropyladenosine (R-PIA) were tested for their anti-tumor necrosis factor (TNF) activities in an endotoxin-induced shock rat model. All the drugs reduced serum TNF concentrations in a dose-dependent manner, whereas their effects on serum interleukin-6 levels differed. Doses that reduced TNF levels by 50% were 0.012 mg/kg for dexamethasone, 0.06 mg/kg for R-PIA, 0.24 mg/kg for pentamidine, 6.5 mg/kg for fusidic acid and 15 mg/kg for pentoxifylline. Administration of the drugs to rats before intraplantar injection of carrageenan reduced paw edema by 50-70%. Injection of a monoclonal anti-TNF antibody reproduced the inhibitory effect. Moreover, the time course of tissue-associated TNF following carrageenan injection was compatible with mediation of edema by TNF. Results obtained for this acute, non-immunological inflammatory reaction strongly suggest that the model is TNF-dependent. Our results reinforce the idea that TNF is a crucial target in the therapeutics of inflammatory reactions. These drugs, which are able to cross cell barriers, might have clinical applications in localized and/or chronic diseases in which TNF is involved.

Acute-Phase Reaction

Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat.

Intravenous treatment of male rats with recombinant human interleukin-6 (rhIL6) at 50, 100 and 200 micrograms/kg (corresponding to 4, 8 and 16 x 10(4) U/animal, respectively) reduced the activities of hepatic microsomal cytochrome P450-dependent monoxygenases to varying degrees. Ethylmorphine-N-demethylase activity fell to 53% of control values, an effect similar to that induced by 2.5 mg/kg Escherichia coli lipopolysaccharide (LPS). Ethoxycoumarin-O-deethylase activity was also sensitive to inhibition, whereas IL6 had little effect on the activities of other P450-dependent enzymes, including ethoxyresorufin-O-deethylase. Pentoxyresorufin dealkylase activity, which is representative of the cytochrome P450 IIB 1/2 subfamily, was unaffected by IL6 whereas LPS reduced it to 33.7% of control values. Another hepatocyte-related parameter, serum concentration of alpha 1-acid glycoprotein (AGP), was increased by up to 3.5-fold over baseline by IL6 and 10-fold by LPS. Recombinant human interleukin-1 beta (rhIL1 beta) (10 micrograms/kg, corresponding to 5 x 10(4) U/rat) and recombinant human tumor necrosis factor alpha (rhTNF) (150 micrograms/kg corresponding to 24 x 10(4) U/rat) were both as potent as LPS (2.5 mg/kg) in increasing serum AGP levels and reducing hepatic microsomal monoxygenase activities. IL6 did not potentiate the effects of rhIL1 beta. Hepatic microsomal glucuronyltransferase activities were little affected by LPS and unaffected by rhIL6. Finally, rhIL6 was more potent after i.p. injection than after i.v. or s.c. injection. These results suggest that the effects of LPS, TNF and IL1 on the mixed-function oxidase system in vivo may be due partly to an induction of IL6 in vivo. The different sensitivities of the enzymes to IL6 but not to IL1 or TNF may be due to the involvement of two distinct mechanisms.

Animals

Modifications of hepatic alpha-1-acid glycoprotein and albumin gene expression in rats treated with phenobarbital.

The serum level of alpha 1-acid glycoprotein (alpha 1-AGP) is significantly increased in various animal species by treatment with cytokines, glucocorticoids and phenobarbital. The mechanisms responsible for the cytokine-induced and glucocorticoid-induced increases are now well documented, but not so in the case of phenobarbital. The main purpose of this study was to assess whether phenobarbital acts on alpha 1-AGP synthesis in the liver at the transcriptional or translational level. Male Dark Agouti rats received 70 mg phenobarbital/kg daily for 7 days. The analysis of total hepatic RNA showed that a single injection of phenobarbital induced an 11-fold increase in phenobarbital-dependent cytochrome P450IIB mRNA, whereas seven injections of phenobarbital were required to induce a maximum 5.5-fold increase in alpha 1-AGP mRNA. Concurrently, the transcription rate of the alpha 1-AGP gene rose 3.5-fold. Hepatocytes isolated after the seventh injection of phenobarbital showed a threefold increased capacity to secrete alpha 1-AGP, corresponding to a 3.2-fold increased alpha 1-AGP mRNA content in the liver. In conditions in which its effect on the induction of alpha 1-AGP synthesis was maximum, phenobarbital caused a 30% reduction in liver albumin mRNA and in albumin secretion by isolated hepatocytes, resulting from a 60-70% reduction in the rate of transcription of the albumin gene measured in isolated nuclei. We conclude that the effect of phenobarbital on alpha 1-AGP and albumin gene expression occurs at the transcriptional rather than the translational level.

Albumins

Recombinant human interleukin 1 beta and tumor necrosis factor affect glycosylation of serum alpha 1-acid glycoprotein in rats.

Serum concentration and glycosylation of rat alpha 1-acid glycoprotein (alpha 1-AGP) were evaluated after the in vivo administration of recombinant human interleukin-1 beta (rhIL-1 beta) and tumor necrosis factor alpha (rhTNF-alpha), alone or associated. The effect of LPS and turpentine was also studied. In all models, serum alpha 1-AGP concentrations were increased and glycosylation was altered. The alpha 1-AGP levels reached 1.8 g/liter with cytokines alone, 2.1 g/liter with cytokines associated or LPS, and 3.4 g/liter with turpentine. Analysis by concanavalin A (Con A) affinoimmunoelectrophoresis (CAIE) revealed that the relative proportion of Con A unreactive form always decreased whatever the inducing agent. On the other hand, the resulting effect on the concentrations of Con A unreactive alpha 1-AGP concentrations was an increase with cytokines alone or LPS and a decrease with cytokines associated or turpentine. These results suggest a dissociation between the alteration in the level of alpha 1-AGP synthesis and in the pattern of its glycosylation in the various inflammatory models.

Acute-Phase Reaction

Nitric oxide mediates the depression of lymphoproliferative responses following burn injury in rats.

Among the multiple biological activities of nitric oxide (NO) an immunoregulatory role consisting of the mediation of macrophage suppressive activity, has recently been evidenced. In the present work, we investigated whether NO was implicated in immunosuppression following burn injury. Thermal injury affecting 20-25% of the total body surface area in Wistar rats, provoked a biphasic depression of spleen cell proliferative responses to phytohemagglutinin (PHA) and concanavalin A (Con A). We show that these responses are fully restored on day 4 after burn and only by 55% on day 10 when spleen cells were stimulated in the presence of NG-monomethyl-L-arginine (NMMA), a potent inhibitor of the macrophage inducible NO synthase. Nitrite content in culture supernatant, as an indicator of NO release (in the absence of NMMA), was significantly augmented in Con A-stimulated spleen cells from burned rats as compared to normal spleen cells. These results show for the first time that NO is implicated, at least in part, in an immunosuppression state which is not linked to an infectious disease.

Animals

Influence of muramyl dipeptide on established experimental arthritis in rats.

The effects of MDP, a potent inducer of cytokines, were studied in four batches of Wistar Furth rats with established experimental arthritis. Arthritic rats were given a daily sc injection of 10, 100, 200 or 400 micrograms MDP respectively. Muramyl dipeptide increased the severity of clinical events in a dose-dependent manner, with the exception of the 10 micrograms dose which was ineffective. The levels of anti-collagen antibodies were not however significantly enhanced by MDP. Radiological lesions and histological changes were maximal at high dosage regimens. Paradoxically, the acute phase reactive alpha 1 glycoprotein was little affected by MDP treatment.

Acetylmuramyl-Alanyl-Isoglutamine

Modification of inflammatory processes by phenobarbital in rats.

Enzyme-inducing drugs such as phenobarbital (PB) increase serum concentrations of an acute-phase protein, alpha 1-acid glycoprotein (AGP), in man, dogs, and rats via an unknown mechanism. We studied the effects of PB on components of an acute inflammatory reaction in rats in order to determine if PB acts only on this biological marker of inflammation or is capable of altering the clinical course of inflammatory processes. Local carrageenan injection induces a similar time-dependent plantar edema and increases serum AGP levels in Sprague-Dawley (SD) and Dark Agouti (DA) rats. Pretreatment with PB for seven days modified neither parameter in SD rats while plantar edema was aggravated and serum AGP levels were increased in DA rats. The sedative-hypnotic properties of PB were not involved, since a single administration of this drug had no action in DA rats. On the other hand, chronic PB administration reduced the severity of an autoimmune disease, type II collagen-induced arthritis, in DA rats. These data indicate that PB, a potent inducer a cytochrome P-450-dependent enzymes, modifies the course of the inflammatory process. Preliminary results with macrophage transfer experiments suggest that this response to PB could be mediated by stimulated macrophages.

Acute Disease

Effect of aging on the pharmcokinetics of atenolol, metoprolol and propranolol in the rat.

The pharmacokinetics of three beta adrenoceptor blocking drugs atenolol, metoprolol, propranolol and of the model drug antipyrine were studied in 3-, 12- and 24-month-old rats. Alpha-1-acid glycoprotein in plasma was slightly increased and the free fraction of propranolol was slightly decreased in the 24-month-old rats. For the four drugs studied, the volume of distribution and the clearance were decreased in the older rats. For propranolol, metoprolol and antipyrine these decreases were already observed in 12-month-old rats, for atenolol only in the 24-month-old rats. There was no change in half-life as a function of age for the three beta blockers; for antipyrine a significant increase in half-life was seen. The decreased volume of distribution suggests a lower tissue binding or a decrease in total body fluid. The change in clearance in function of age can probably be explained for metoprolol and propranolol by a decrease in hepatic blood flow as no change in metabolism or protein binding occurs, for atenolol by a decrease in renal function and for antipyrine by a decrease in metabolism. After p.o. administration of the beta blockers, no significant increase in area under the plasma drug concentration-time curve was observed for propranolol and metoprolol as a function of age, but for atenolol, a significant increase in area under the plasma drug concentration-time curve was seen in the 24-month-old rats, due to a decrease in renal function, as bioavailability of atenolol did not change in function of age.

Aging

Delipidation of alpha 1-acid glycoprotein. Propranolol binding to this glycoprotein and its modification by extracted material and exogenous lipids.

Propranolol binding to human alpha 1-acid glycoprotein (AAG) delipidated by two methods is described. Commercial AAG (99% pure) was either precipitated by ethanol-acetone and then washed by ether, or it was precipitated by ethanol. Binding capacity was quantified by the product n x Ka where n denotes the number of binding sites and Ka the association constant (M-1). Propranolol binding to nondelipidated AAG (n x Ka = 0.113 +/- 0.013 microM-1) was clearly increased after precipitation by ethanol-acetone (n x Ka = 0.386 +/- 0.109 microM-1) or precipitation by ethanol (n x Ka = 0.312 +/- 0.096 microM-1). Binding capacity potentiation cannot be due to modification of AAG microheterogeneity forms, as two-dimensional gel electrophoresis pattern of AAG in presence of concanavalin A was not altered after both methods. Recombination of precipitated AAGs with supernatant dry residue resulted in the abrogation of observed potentiation. Moreover, addition of a polar lipid, linoleic acid, (from 30 to 300 microM) strongly inhibited propranolol binding. These results indicated that glycoprotein precipitation by ethanol provided a simple method to further study binding inhibitors associated with isolated AAG.

Chemical Phenomena

Alpha-1-acid glycoprotein concentrations and protein binding of propranolol in Sprague-Dawley and Dark Agouti rat strains treated by phenobarbital.

Propranolol binding to rat serum samples was studied after 7 days of phenobarbital (PB) administration to induce alpha-1-acid glycoprotein (AAG). In male Sprague-Dawley rats, serum AAG concentrations and the bound/free propranolol ratio (B/F) were increased slightly after enzyme-inducing drug administration (mean +/- S.D.): from 0.30 +/- 0.04 to 0.49 +/- 0.05 g/l for AAG and from 6.79 +/- 1.24 to 8.81 to 1.31 for B/F. In male DA (Dark Agouti) rats, the same parameters increased greatly: from 0.20 +/- 0.01 to 1.38 +/- 0.13 g/l for AAF and from 8.75 +/- 1.01 to 27.15 +/- 3.28 for B/F. PB concentrations determined on the same serum samples were similar in both rat strains. Female DA rats also were responsive to PB administration. Propranolol binding to DA rat serum from the treated group was characterized by an increase in high-affinity binding site concentrations. The binding of propranolol to isolated rat AAG at various concentrations (0.2-1 g/l), alone or associated with rat serum albumin at a constant concentration (36 g/l), also was studied. Propranolol binding capacities to rat AAG were increased 2.4 times by the presence of albumin and consequently B/F values for both proteins agreed with values obtained with serum samples. These results indicate that increased propranolol binding to rat serum induced by PB administration is probably a direct consequence of increased concentrations of AAG. The high sensitivity of DA rats to PB suggests that this strain should be used preferentially for the study of the effect of cytochrome P-450 inducers on AAG metabolism and cationic drug binding.

Animals

Structural identifiability of "first-pass" models.

This paper considers the structural identifiability of two compartmental models classically used to describe the pharmacokinetics of drugs orally administered and transformed into a metabolite with a first-pass effect at the hepatic level. The simplest model proves not to be globally identifiable even when plasma and urinary measurements of the drug and metabolite concentrations are made. It admits two sets of admissible solutions, so that a priori knowledge must be introduced to distinguish them. The more complex model appears globally identifiable when blood and urine measurements are made.

Humans

Effect of recombinant human interleukin-1 beta and tumor necrosis factor alpha on liver cytochrome P-450 and serum alpha-1-acid glycoprotein concentrations in the rat.

Two hepatocyte-related effects of recombinant human interleukin-1 beta and tumor necrosis factor alpha alone or in association were tested following iv administration to Fischer 344 rats. Within 24 hr, both monokines induced a dose-dependent decrease in cytochrome P-450 levels, whereas serum alpha-1-acid glycoprotein concentrations were strongly increased. The largest variation of both parameters was observed using a combination of the two monokines. Dexamethasone, which possesses anti-interleukin-1 properties and is known to stimulate alpha-1-acid glycoprotein synthesis in rats, also depressed cytochrome P-450 levels, suggesting that alpha-1-acid glycoprotein might mediate the monokine-related inhibition of drug metabolism. Nevertheless, at the lowest doses of monokines tested, only cytochrome P-450 levels were modified. The transfer of a post-dexamethasone serum to normal rats did not change cytochrome P-450 levels.

Animals